# A Randomized, Controlled, Multicenter Trial of Filgrastim (Recombinant-Methionyl Human Granulocyte Colony Stimulating Factor; G-CSF) for the Prevention of Grade 4 Neutropenia in Patients With HIV Infection.

> **NCT00002126** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 250 (—)

## Conditions studied

- HIV Infections
- Cytopenias

## Interventions

- **DRUG:** Filgrastim

## Key facts

- **NCT ID:** NCT00002126
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 250 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002126, "A Randomized, Controlled, Multicenter Trial of Filgrastim (Recombinant-Methionyl Human Granulocyte Colony Stimulating Factor; G-CSF) for the Prevention of Grade 4 Neutropenia in Patients With HIV Infection.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00002126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*